Safety and Efficacy of MBI 226 2.5% and 5.0% Topical Acne Solutions in the Treatment of Acne

• Status: Completed
• Trial end date: 2001-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study investigates the safety and efficacy of MBI 226 2.5% and 5.0% Acne Solutions, applied topically for six weeks, in the treatment of acne.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: BioWest Therapeutics Inc
• Treatments: Antimicrobial Cationic Peptides; Omiganan pentahydrochloride; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Males and females, ages 13 and up, exhibiting high levels of facial P. acnes

• Presence of inflammatory and non-inflammatory lesions

Exclusion Criteria:

• Acne conglobata, acne fulminans, or secondary acne (chlorine, drug-induced acne, etc.)

• Active facial cysts